Sulfadiazine is a sulfonamide anti-infective drug commonly used in China at present. It is also known as sulfapyridazine and diazepam. Sulfadiazine has a molecular structure similar to p-aminobenzoic acid (PABA) and can compete with PABA in the body of bacteria. Dihydrofolate synthase, which prevents PABA from being used as a raw material to synthesize the folic acid required by bacteria, reduces the amount of metabolically active tetrahydrofolate, which is used by bacteria to synthesize purine, thymidine, and deoxyribonucleic acid (DNA) Essential substances, thus inhibiting the growth and reproduction of bacteria. Sulfadiazine is sensitive to hemolytic streptococcus, staphylococcus, meningococcus, pneumococcus, gonococcus, Escherichia coli, dysentery bacillus, etc. as well as Chlamydia trachomatis, actinomycetes, malaria parasite, nostril aureus and toxoplasma, etc. Microorganisms have inhibitory effects.
Sulfa drugs are broad-spectrum antibacterial drugs, but because many clinically common pathogenic bacteria are resistant to these drugs, they are only used for infections caused by sensitive bacteria and other sensitive pathogenic microorganisms. The main indications for sulfadiazine (excluding the compound preparation of this drug and trimethoprim) are as follows:
(1) Treatment and prevention of epidemic cerebrospinal meningitis caused by sensitive meningococci.
(2) Combined with trimethoprim, it can treat otitis media and skin and soft tissue infections caused by Haemophilus influenzae, Streptococcus pneumoniae and other streptococci that are sensitive to it.
(3) Aspergillosis.
(4) Adjuvant medication for the treatment of falciparum malaria resistant to chloroquine.
(5) The second choice for the treatment of cervicitis and urethritis caused by Chlamydia trachomatis.
(6) The second choice for the treatment of neonatal inclusion body conjunctivitis caused by Chlamydia trachomatis.